Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 15/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151871 | 1.00 | CA1 (0.40) | CA1CA2CA4CYP1A2CNR2 | |
| SCHEMBL4840177 | 1.00 | CA1 (0.40) | CA1CA2CA4CYP1A2CNR2 | |
| SCHEMBL14646885 | 1.00 | CA1 (0.40) | CA1CA2CA4CYP1A2CNR2 | |
| SCHEMBL6127788 | 1.00 | CA1 (0.40) | CA1CA2CA4CYP1A2CNR2 | |
| SCHEMBL4843048 | 0.95 | CA1 (0.45) | CA1CA2CA4CYP1A2CNR2 | |
| Cyclohexanol SCHEMBL11225955 | 0.94 | CYP1A2 (0.43) | CA1CA2CA4CYP1A2CNR2 | |
| SCHEMBL4843706 | 0.93 | CYP1A2 (0.46) | CA1CA2CA4CYP1A2CNR2 | |
| SCHEMBL10409624 | 0.93 | CA1 (0.41) | CA1CA2CA4CYP1A2CNR2 | |
| SCHEMBL4843185 | 0.87 | CYP1A2 (0.56) | CYP1A2CNR2 | |
| SCHEMBL4845449 | 0.86 | CYP1A2 (0.46) | CA1CA2CA4CYP1A2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | CA1 2719/4885CA2 1934/4885CA4 3899/4885 |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | CA1 2981/4885CA2 2126/4885CA4 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.